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CD40-directed scFv-TRAIL fusion proteins induce
CD40-restricted tumor cell death and activate
dendritic cells
M El-Mesery1,2, J Trebing1, V Scha¨fer1, D Weisenberger1, D Siegmund1 and H Wajant*,1
Targeted cancer therapy concepts often aim at the induction of adjuvant antitumor immunity or stimulation of tumor cell
apoptosis. There is further evidence that combined application of immune stimulating and tumor apoptosis-inducing compounds
elicits a synergistic antitumor effect. Here, we describe the development and characterization of bifunctional fusion proteins
consisting of a single-chain variable fragment (scFv) domain derived from the CD40-specific monoclonal antibody G28-5 that is
fused to the N-terminus of stabilized trimeric soluble variants of the death ligand TNF-related apoptosis-inducing ligand (TRAIL).
As shown before by us and others for other cell surface antigen-targeted scFv-TRAIL fusion proteins, scFv:G28-TRAIL displayed
an enhanced capacity to induce apoptosis upon CD40 binding. Studies with scFv:G28 fusion proteins of TRAIL mutants that
discriminate between the two TRAIL death receptors, TRAILR1 and TRAILR2, further revealed that the CD40 binding-dependent
mode of apoptosis induction of scFv:G28-TRAIL is operable with each of the two TRAIL death receptors. Binding of scFv:G28-
TRAIL fusion proteins to CD40 not only result in enhanced TRAIL death receptor signaling but also in activation of the targeted
CD40 molecule. In accordance with the latter, the scFv:G28-TRAIL fusion proteins triggered strong CD40-mediated maturation of
dendritic cells. The CD40-targeted TRAIL fusion proteins described in this study therefore represent a novel type of bifunctional
fusion proteins that couple stimulation of antigen presenting cells and apoptosis induction.
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Ligands and receptors of the tumor necrosis factor (TNF)
family fulfill central roles in immune regulation and main-
tenance of tissue homeostasis mainly by control of inflamma-
tory and cell death-inducing pathways. TNF receptors are
characterized by a conserved cysteine-rich domain (CRD)
that is present in one to six copies in their extracellular
domain1 With the exception of a few soluble or GPI-anchored
decoy receptors, all TNF receptors are single spanning
transmembrane receptors that have the capability to trigger
proinflammatory signaling pathways. Structurally, a subgroup
of TNF receptors can be defined as the so-called death
domain-containing receptors. The intracellular domain of
these receptors contains a conserved protein–protein inter-
action domain, the death domain, and some of the death
receptors are able to directly trigger signaling pathways that
result in apoptotic and/or necrotic cell death, for example,
CD95 and TRAILR1 and TRAILR2, two of the five receptors of
the TNF-related apoptosis-inducing ligand (TRAIL).1
Defects in ligands and receptors of the TNF family or their
deregulated expression are of pivotal relevance in a variety of
diseases and pathologies. Indeed, antibodies and recombi-
nant proteins targeting RANKL or TNF and its receptors are
already in use in clinical practice and many more reagents
targeting ligands and receptors of the TNF family are currently
tested in clinical trials.2 With respect to tumor therapy, a whole
range of TNF receptors are considered as useful targets. On
the one hand, immune stimulatory TNF receptors, such as the
T-cell coactivatingmolecules 41BB, CD27, OX40 andGITR or
the dendritic cell (DC) activator CD40 are of interest for
immuno-therapeutic treatments. On the other hand, the above
mentioned death receptors attract attention as apoptosis-
inducing targets. This especially applies for TRAILR1 and
TRAILR2 because there is good evidence that TRAIL
predominately acts on tumor cells and the tumor vasculature
but largely spares non-transformed cells and tissue.3 It is
noteworthy that concomitant activation of immune stimulatory
and tumor cell death-inducing TNF receptors can result in a
synergistic antitumoral effect as presentation of tumor-
derived peptides and thus the effects of immune stimulatory
TNF receptors are improved if there is in parallel an increase
in dead tumor cells.
Exogenous activation of TNF receptors is typically achieved
by the use of two types of reagents, antibodies and
recombinantly produced soluble TNF ligand variants. The
development and use of both types of reagents require the
consideration of a couple of issues. With respect to TNF
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receptor-specific antibodies, for example, one has to keep in
mind that their agonistic activity can be highly dependent on
binding to Fcg receptors (FcgRs). Thus, the activity of such
agonistic antibodies is in vivo highly dependent on the
availability of FcgRs-expressing cells in the microenvironment
of target-expressing cells as well as on the isotype of the
antibody.4–7Another important issue in this context is that
in vivo agonistic antibodies not only act by TNF receptor
activation but also, and often even more prominent, by the
recruitment of immune cells and stimulation of immune
effector functions, such as antibody-dependent cellular
cytotoxicity (ADCC) and CDC. However, stimulation of TNF
receptors with soluble TNF ligands is also not ever straight-
forwardly possible for the following reason: ligands of the TNF
family are normally expressed as membrane-bound proteins,
although soluble variants also occur physiologically due to
proteolytic processing or alternative splicing. Now, the
interaction of TNF receptors with membrane-bound TNF
ligands always results in strong receptor activation, whereas
TNF receptors respond differently to binding of soluble ligand
molecules. Some TNF receptors are strongly activated by the
binding of soluble ligands, whereas others bind soluble
ligands but then fail to trigger intracellular signaling.8 In the
latter case, the lacking or poor response to the binding of a
soluble TNF ligand can be overcome by two means, either by
ligand oligomerization or by artificial cell surface anchoring of
the ligand exploiting an additional TNF receptor-independent
interaction with a cell surface exposed molecule.8 Indeed, this
is also relevant in the TRAIL–TRAILR system. Especially for
TRAILR2, there is broad experimental evidence that binding
of soluble TRAIL trimers is insufficient to trigger a significant
apoptotic response, whereas secondarily oligomerized TRAIL
trimers or trimeric single-chain variable fragment (scFv)–
TRAIL fusion protein that have bound to a cell surface antigen
are potent inducers of apoptosis.9–12
Here, we describe the development of trimeric CD40-
specific scFv fusion proteins of TRAIL and TRAILR1- and
TRAILR2-specific TRAIL mutants that do not only show high
CD40-restricted apoptotic activity but also concomitant
activation of CD40. Thus, this new type of bifunctional fusion
proteins combines a strong immune stimulating effect on DCs
with the concomitant induction of tumor cell death via the
TRAIL death receptors.
Results
Binding to CD40 enhances apoptosis induction by
scFv:G28-TRAIL. To achieve targeting of soluble trimeric
TRAIL to CD40, we constructed a fusion protein, termed in
the following as scFv:G28-TRAIL, consisting of a Ig signal
peptide followed by a scFv derived from the human CD40-
specific mAb G28-5 and aa 95-281 of human TRAIL
encompassing its C-terminal TNF homology domain. An
internal Flag epitope and the short 3 kDa trimerization
domain of tenascin-C (TNC) were placed between the scFv
and TRAIL domains (Figure 1a). The Flag epitope facilitates
the detection and purification, whereas the TNC domain
stabilizes the trimeric assembly of the fusion protein, which is
driven by the TRAIL domain (Figure 1a). Supernatants
collected from Hek293 cells stably transfected with the
scFv:G28-TRAIL-encoding expression plasmid were subjected
to affinity chromatography purification on anti-Flag agarose
resulting in fairly pure preparations of the scFv-TRAIL fusion
protein (Figure 1b). To initially evaluate the inherent
functionality of the scFv and TRAIL domain of scFv:G28-
TRAIL, the cytotoxic effect on CD40-negative Jurkat cells
and binding to CD40 transfectants were analyzed. In contrast
to Flag-TNC-TRAIL, the scFv:G28-TRAIL fusion protein
showed a significant cytotoxic effect on Jurkat cells between
20 and 200ng/ml. More important, however, both molecules
elicited a comparable strong cytotoxic effect on Jurkat cells
upon oligomerization with the antibody M2 recognizing the
internal Flag tag of the two molecules (Figure 1c). It is very
well established that soluble TRAIL trimers only induce
efficient cell death in Jurkat cells upon oligmerization.11,12
Thus, scFv:G28-TRAIL preparations appear to contain
a minor fraction of oligomerized molecules causing the
observed apoptosis induction at higher concentrations but
otherwise have the same intrinsic apoptotic capacity as
Flag-TNC-TRAIL. Analysis of the binding of scFv:G28-TRAIL
to HeLa cells and HeLa-CD40 transfectants as well as
to HT1080 and HT1080-CD40 transfectants by FACS
further demonstrated the functionality of the scFv domain
(Figure 1d).
Next, we analyzed whether, and if yes to which extent,
CD40 cell surface expression influences the apoptotic activity
of scFv:G28-TRAIL. HT1080-CD40 and HeLa-CD40 trans-
fectants along with their corresponding CD40-negative
counterparts were challenged with increasing concentrations
of scFv:G28-TRAIL, and the following day the viability of the
cells were determined by crystal violet staining. In parental
HeLa and HT1080 cells, there were only partial killing even at
the highest concentration of 200 ng/ml used in these experi-
ments (Figure 2a). In parallel, the CD40-expressing transfec-
tants were almost completely killed at concentrations of
around 10 ng/ml and showed a shift of the ED50-values for cell
death induction of approximately two orders of magnitude
toward lower concentrations (Figure 2a). CD40-dependent
enhancement of apoptosis induction by scFv:G28-TRAIL was
also evident from experiments, where four different cell lines
with endogenous CD40 expression were challenged in the
presence and absence of a Fc fusion protein of scFv:G28
that competes with scFv:G28-TRAIL for CD40 binding
(Figures 2b and c). Not unexpected, enhanced cell death
induction of CD40-expressing cells by scFv:G28-TRAIL was
reflected by stronger activation of caspases (Figure 3). This is
in accordance with the idea that the enhanced cytotoxic
effects of scFv:G28-TRAIL on CD40-expressing cells are due
to enhanced stimulation of TRAIL death receptor-mediated
apoptosis. To further proof the possibility that CD40-bound
scFv:G28-TRAIL also acts on neighboring CD40-negative
cells, we exploited that CD40-expressing Rec-1 cells on the
one hand are TRAIL-resistant (Figures 4a and b) and that on
the other hand Jurkat cells are only killed by oligomerized or
cell surface immobilized TRAIL trimers.10,12,13 As shown in
Figure 1c, without oligomerization scFv:G28-TRAIL induced
cell death in Jurkat cells only between 20 and 200ng/ml and
there was no significant cell death at lower concentrations.
Indeed, there was almost no caspase activation in individual
cultures of Jurkat and Rec-1 cells treated with 5 ng/ml of
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scFv:G28-TRAIL, whereas in cocultures of these two cell lines
there were significant induction of caspase activation in
response to treatment with scFv:G28-TRAIL (Figure 4c). In
accordance with the idea of paracrine killing of CD40-negative
Jurkat cells by Rec-1-bound scFv:G28-TRAIL, cell death
induction and caspase activation in cocultures by the latter
were diminished in the presence of scFv:G28-2xFlag-GpL as
a competitor (Figures 4c and d). Together these experiments
argue for the ability of scFv:G28-TRAIL to induce bystander
apoptosis in CD40-negative cells.
CD40 binding-dependent activity of TRAILR1- and
TRAILR2-specific scFv:G28-TRAIL variants. In the recent
years several mutations have been described for TRAIL that
confer at least to some extent specificity for TRAILR1 and
TRAILR2 (for review see Wajant et al.8). To evaluate the
potential of such mutations for the generation of TRAILR1- or
TRAILR2-specific scFv-TRAIL fusion proteins with
CD40-restricted activity, we replaced the TRAIL wild-type
domain of scFv:G28-TRAIL by the TRAIL mutants
G131R/R149I/S159R/N199R/K201H/S215D (mutR1) and
Y189Q/R191K/Q193R/H264R/I266L/D267Q (mutR2) that
preferentially bind to TRAILR1 (TRAILmutR1) and TRAILR2
(TRAILmutR2)14,15 and showed good discrimination for
TRAILR1 and TRAILR2 in the cellular binding assays and
functional assays (manuscript submitted). In the following,
we analyzed to which extent CD40 binding impacts the
apoptotic activity of scFv:G28-TRAILmutR1 and scFv:G28-
TRAILmutR2. Side by side analysis of CD40 transfectants
with their CD40-negative counterparts as well as the analysis
of cells with endogenous CD40 expression in the absence
and presence of the competitor scFv:G28-Fc-GpL revealed
significantly enhanced apoptotic activity for both constructs
upon CD40 binding (Figures 5a, b and 6a, b).
Induction of DC maturation by scFv:G28-TRAIL. Against
the background that the parental G28-5 antibody acts at least
in some scenarios as an agonist and furthermore due to
reports showing that other antibodies targeting members of
the TNF receptor family exert agonistic activity after
oligomerization or FcgR binding,4,6 we wondered whether
scFv:G28-TRAIL could act as a stimulator of CD40 signaling.
Figure 1 Domain architecture of the scFv:G28 fusion proteins used in this study and initial analysis of scFv:G28-TRAIL. (a) Schemes of scFv:G28-TRAIL, scFv:G28-
2xFlag-GpL, scFv:G28-Fc-GpL and scFv:G28-TNC-GpL. scFv:G28, scFv derived from the human CD40-specific mAb G28-5; Flag epitope; TNC, trimerization domain, aa
110-139 of chicken tenascin-C; TRAIL, aa 95-281 of human TRAIL; Fc, CH3 domain of hIgG1; GpL, luciferase of Gaussia princeps. scFv:G28-Fc-GpL and scFv:G28-2xFlag-
GpL were used as competitors for scFv:G28-TRAIL. scFv:G28-TNC-GpL were used to analyze the effect of trimerization of scFv:G28 on CD40 activity. (b) Anti-Flag affinity
chromatography purified scFv:G28-TRAIL (100 ng) was subjected to SDS-PAGE and visualized by silver staining. (c) Jurkat cells (60 103 per well; 96-well plate) were
challenged in the absence and presence of the anti-Flag mAb M2 (1 mg/ml) with the indicated concentrations of scFv:G28-TRAIL or its conventional counterpart Flag-TNC-
TRAIL. Next day, cellular viability was determined by using the MTT assay (d) HeLa and HT1080 cells along with the corresponding CD40 transfectants were incubated with
scFv:G28-TRAIL (500 ng/ml) and after three washes, bound molecules were detected by FACS using anti-Flag mAb M2-FITC
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Initially, we investigated Hela cells and HeLa-CD40 transfec-
tants with respect to the activation of signaling pathways
leading to IL-8 production. scFv:G28-TRAIL indeed triggered
the latter in HeLa-CD40 cells but not in HeLa cells
(Figure 7a). In principle, TRAIL and the TRAIL death
receptors can also trigger the aforementioned proinflamma-
tory response, but we found in a former study that this
depends in HeLa cells on sensitization for TRAILR1/2
signaling by CHX and blockade of apoptosis.16
Indeed, Killer-TRAIL, a commercially available active form
of TRAIL exerted only a weak IL-8-inducing effect in
HeLa-CD40 cells, although it triggered apoptosis with high
efficiency under CHX-sensitized conditions (Figure 7b).
The major aim of many therapeutic concepts that base on
CD40 targeting is the stimulation of DCmaturation to enhance
antitumor immunity.6 We therefore analyzed the effect of
scFv:G28-TRAIL on immature and mature monocyte-derived
DCs. Despite the strong expression of CD40 on DCs,
Figure 2 CD40 binding enhances apoptosis induction by scFv:CD40-TRAIL. (a) HT1080-CD40 and HeLa-CD40 transfectants and the corresponding parental cell lines
were seeded in 96-well plates and were stimulated the next day in triplicates with the indicated concentration of scFv:G28-TRAIL. After an additional day, cellular viability was
determined by crystal violet staining and normalized the help of untreated cells and a cell sample treated with mixture of toxic compounds. Cells were sensitized with CHX
(2.5mg/ml) to enhance apoptosis. (b) OVCAR3, BJAB, Mino, 786-O and CD40-negative Jurkat cells were analyzed for endogenous CD40 expression by FACS. (c) Triplicates
of cells were treated in 96-well plates with the indicated concentrations of scFv:G28-TRAIL in the presence and absence of scFv:G28-Fc-GpL (2 mg/ml) as a competitor. Next
day, cellular viability was determined by crystal violet staining or using the MTT assay
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scFv:G28-TRAIL variants were not or only poorly toxic against
immature and mature DCs (Figures 8a and b). Noteworthy,
however, scFv:G28-TRAIL was similarly effective with
respect to the stimulation of DC maturation as a mixture of
TNF, IL-6, IL1-b and prostaglandin E2 (PGE2), the gold
standard for in vitro DC maturation. All scFv:G28-TRAIL
variants as well as a tenascin-C trimerization domain-contain-
ing variant of scFv:G28 domain (scFv:G28-TNC-GpL) trig-
gered the upregulation of CD83 and CD86 and also induced
IL12 release (Figures 8c and d). In contrast, Killer-TRAIL did
not show any effects indicating DC maturation (Figures 8c
and d). Although heat-inactivation had no major effect on
lipopolysaccharide (LPS)-induced IL12 release, it completely
destroyed the IL12-inducing activity of the various scFv:G28-
TRAIL samples (Figures 8c and d). Vice versa, polymyxin B
treatment inhibited LPS-induced IL12 release, whereas it left
scFv:G28-TRAIL-induced IL12 production largely unaffected
(Figure 8e). The reciprocal effect of heat-inactivation and
polymyxin B treatment on LPS- and scFv:G28-TRAIL-induced
IL12 production indicates that the latter was primarily
triggered by scFv:G28-TRAIL and not by endotoxin contam-
inations. In sum, our data suggest that scFv:G28-TRAIL
variants act as bifunctional reagents that not only trigger cell
death in tumor cells but also stimulate DC maturation.
Discussion
Early on after the discovery of TRAIL and the TRAIL death
receptors, it became apparent that TRAIL induces apoptosis
in a variety of tumor cell lines but sparse the huge majority of
non-transformed cells. In view of this finding, it cannot be a
real surprise that considerable efforts have been made by
several groups and companies to develop and evaluate
TRAIL/TRAIL death receptor-based cancer therapeutics.
Indeed, a variety of clinical phase I and II trials using
recombinant TRAIL or TRAIL death receptor-targeting anti-
bodies are ongoing or have been recently completed.17,18
These trials confirmed the anticipated good safety profile of
TRAIL death receptor-targeting reagents as single therapy
and in combination with several other drugs but also revealed
comparably moderate antitumor activities.17,18 The latter
might be related to two major issues. First, there is compelling
evidence from in vitro studies and preclinical models that there
exist many mechanisms conferring TRAIL resistance to tumor
cells which, however, can be overcome by combination with
appropriate drugs that preferentially resensitize cancer cells.
However, the TRAIL death receptor-targeting drug regimens
have been applied so far to poorly selected groups of patients,
as appropriate biomarkers are missing.17,18 Second, the
currently used TRAIL death receptor-targeting reagents
presumably do not fully exploit the apoptotic signaling
capabilities of TRAILR1/TRAILR2. In a subset of members
of the TNF receptor superfamily, including TRAILR2, the
binding of soluble ligand trimers is less efficient in receptor
activation than interaction with the corresponding membrane-
bound form of the ligand.8 Now, in these cases maximal
receptor stimulation by soluble ligand trimers can be restored
by secondary ligand oligomerization or artificial cell surface
immobilization. Noteworthy, the recombinant TRAIL used in
clinical trials corresponds to the less active trimeric soluble
form of the molecule. The molecular basis of the different
activities of TNF receptor complexes with soluble and
membrane-bound (or oligomerized) ligand trimers is still
insufficiently understood, but there is evidence that secondary
Figure 3 Cells were treated as indicated with mixtures of scFv:G28-TRAIL (10 ng/ml), CHX (2.5mg/ml) and scFv:G28-Fc-GpL (2 mg/ml) for 5 h and total cell lysates were
analyzed by western Blot for the presence of the indicated proteins
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assembly of initially formed ligand–receptor complexes into
supramolecular cluster has a decisive role. The need of
supramolecular clustering might also explain the finding that
oligomerized and FcgR-bound TRAILR2-specific antibodies
display enhanced signaling capabilities.7,19,20 Thus, TRAIL
death receptor-targeting antibodies might elicit in vivo sub-
optimal receptor stimulation as long as they are not
oligomerized by binding to FcgR-expressing cells.
We and others have shown earlier for the TRAIL death
receptors and some other members of the TNF receptor
family that their per se poor response to binding of soluble
ligand trimers can be overcome by anchoring the latter to cell
surface antigens. Here, we exploited this principle to develop
CD40-targeted scFv-TRAIL fusion proteins that mimic the
superior activity of oligomerized soluble TRAIL and mem-
brane TRAIL upon binding to CD40. Noteworthy, by the use of
a potentially agonistic CD40-specific scFv domain for CD40
targeting, this approach not only resulted in TRAIL
fusion proteins with enhanced apoptosis-inducing activity
(Figures 2–4) but also tightly connected this to CD40 binding
and CD40 activation (Figures 7 and 8). The linkage of
improved TRAIL activity with binding and activation of CD40
has two considerable advantages compared with non-
targeted TRAIL variants. First, CD40 is highly expressed on
the huge majority of B-cell malignancies and on many solid
tumors. It is also expressed on many immune cells and some
other non-transformed cell types but typically at more
moderate levels. Thus, CD40 is not a bona fide tumor marker
but shows considerable tumor association. Enhanced TRAIL
death receptor activation by CD40 binding, as achieved with
the constructs described in this work, has therefore the
potential to limit the offtarget effects of TRAIL. This property
may become particularly relevant in view of the fact that in
most TRAIL-based therapeutic scenarios, combination with
other drugs that potentially sensitizes normal cells for TRAIL-
induced apoptosis has been envisaged.17,18 Moreover, we
found that the cell surface antigen binding-mediated increase
in activity can also be achieved with TRAIL mutants that
preferentially stimulate TRAILR1 or TRAILR2 (Figures 5 and 6).
Thus, the use of such mutants in combination with CD40
Figure 4 Binding to apoptosis-resistant CD40þ cells enables scFv:G28-TRAIL to induce apoptosis in sensitive CD40 bystander cells. (a) Rec-1 cells were analyzed by
FACS for CD40 cell surface expression. (b) Rec-1 cells were challenged with the indicated concentrations of Killer-TRAIL and analyzed the next day for cellular viability using
the MTT assay. (c) Rec-1 and Jurkat cells were individually cultivated or cocultivated and were stimulated with scFv:G28-TRAIL (5 ng/ml) in the presence and absence of
scFv:G28-2xFlag-GpL (2 mg/ml), a competitor interfering with CD40 binding of scFv:G28-TRAIL. Cells were harvested after 6 h for western blot analysis of caspase processing
(d) Rec-1 and Jurkat cells were cultivated together and were stimulated with the indicated concentrations of scFv:G28-TRAIL in the presence and absence of scFv:G28-
2xFlag-GpL (2 mg/ml). Cells were then analyzed next day with respect to cellular viability using the MTT assay
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targeting principally allows further reduction of potential
TRAIL-related side effects in cases where the latter and the
apoptotic effect in the targeted tumor make differential use of
TRAILR1 and TRAILR2. A second advantage of CD40
targeting with scFv-TRAIL fusions proteins is the accompa-
nied activation of CD40. Indeed, due to its stimulatory effects
on antigen presenting cells and cytotoxic myeloid cells,
agonistic CD40 antibodies are currently investigated in clinical
trials for cancer therapy.6 In this respect, we observed that
scFv:G28-TRAIL strongly induces maturation of monocyte-
derived immature human DCs without causing cell death in
these cells (Figure 8). Thus, CD40-targeting scFv-TRAIL
fusion proteins of the type described in our study have the
potential to trigger concomitantly two independent, potentially
synergistically acting mechanisms namely apoptosis induc-
tion in tumor cells and activation of DCs.
Materials and Methods
Cloning, production and purification of recombinant proteins.
The expression constructs encoding the various scFv:G28-TRAIL fusion proteins,
the monomeric scFv:G28-2xFlag-GpL and the dimeric scFv:G28-Fc-GpL were
obtained by combining appropriate DNA fragments encoding scFv G28-5
(accession number AJ853736) derived from the human CD40-specific mAb
G28-5,21 TRAIL aa 95-281 (accession number U37518), chicken TNC aa 110-139,
human IgG1 aa 222-447, luciferase of Gaussia princeps (GpL) and a Flag epitope
by standard cloning techniques into pCR3 behind an Ig leader. The different
TRAIL fusion proteins were produced and purified essentially as described
elsewhere for similarly structured scFv-TNF ligand fusion proteins.22 In brief,
HEK293 cells were electroporated (50 106 cells/ml, 4-mm cuvette, 250 V,
1800 mF, maximum resistance) with 40mg of the corresponding expression
vectors in 1 ml of culture medium containing 10% FCS using an Easyject Plus
electroporator (PeqLab Biotechnologie, Erlangen, Germany). Electroporated cells
were recovered in RPMI 1640 with 10% FCS, 1% Penicillin (PAA Laboratories,
Co¨lbe, Germany) overnight and were then selected by supplementing the medium
with 0.5 mg/ml Geneticin disulfate (G418-Sulfate, Carl Roth company, Karlsruhe,
Germany) for 4 weeks. For production of the TRAIL fusion proteins, the polyclonal
transfectants were cultivated for 7 days in RPMI 1640 with only 2% FCS.
Supernatants were then collected and clarified by centrifugation. scFv:G28-TRAIL
fusion protein was purified by affinity chromatography on anti-Flag M2 agarose
beads (Sigma-Aldrich, St. Louis, MO, USA) and elution with TBS containing
100mg/ml Flag peptide (Sigma-Aldrich). The fractions containing the recombinant
protein were finally dialyzed against PBS and stored at  201C for further
analysis.
Cell death assay. The adherent cell lines HeLa, HeLa-CD40, HT1080,
HT1080-CD40, 786-O and OVCAR3 (20 103 cells per well) were seeded in
96-well tissue culture plates. The next day, cells were treated in triplicates with the
Figure 5 CD40 binding enhances apoptosis induction by scFv:G28 fusion proteins of TRAILR1- and TRAILR2-specific TRAIL mutants. (a) HT1080-CD40 and HeLa-CD40
transfectants and the respective parental cell lines were stimulated in 96-well plates in triplicates with the indicated concentrations of scFv:G28-TRAIL, scFv:G28-TRAILmutR1
and scFv:G28-TRAILmutR2 in the presence of CHX (2.5mg/ml). Next day, cellular viability was determined by crystal violet staining. (b) OVCAR3 and Mino cells were treated
in triplicates in 96-well plates with the various scFv:G28-TRAIL fusion proteins with and without pretreatment of the cells with scFv:G28-Fc-GpL (30 min, 2mg/ml) as a
competitor. Cellular viability was determined next day by crystal violet staining or the MTT assay
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TRAIL fusion proteins in the presence of CHX (2.5mg/ml). In experiments, where
scFv:G28-Fc-GpL (2mg/ml) was used as a competitor of scFv:G28-TRAIL fusion
proteins for CD40 binding, this compound was added to the cells 30 min prior the
fusion proteins. Cell viability was determined after an additional day by crystal
violet staining. The suspension cell lines Jurkat, Mino, BJAB and Rec-1 were
seeded in 96-well tissue culture plates (60 103 cells per well) and were treated
the same day in triplicates in the absence of CHX in the same manner as
described before for adherent cells. Oligomerization of TRAIL fusion proteins with
the FLAG-specific mAb M2 (1 mg/ml) was performed on a separate 96-well plate
for 30 min before the complexes were added to the cells. Cell viability was
determined the next day by MTT staining. In coculture assay, Jurkat (60 103
cells per well) and Rec-1 (6 103 cells per well) were seeded together 96-well
tissue culture plates. scFv:G28-2xFlag-GpL (2 mg/ml) was added to the cells
30 min prior the fusion proteins as a competitor, and the cells were treated as
described previously for suspension cells.
FACS analysis. To evaluate the binding of TRAIL fusion proteins to HeLa and
HT1080 cells and their corresponding CD40 transfectants, cells were washed with
PBS and incubated on ice for 30 min with scFv:G28-TRAIL (500 ng/ml). Cells were
washed again three times with PBS and incubated on ice for 30 min with anti-Flag
mAb M2-FITC (Sigma-Aldrich). After three washes with ice-cold PBS, samples
were analyzed using a FACSCalibur (BD Biosciences, Heidelberg, Germany).
To determine cell surface expression of CD40, cells were incubated on ice with a
PE-labeled CD40-specific Ab (clone HB14; Miltenyi Biotec, Bergisch Gladbach,
Germany) or an appropriate PE-labeled isotype control (mouse IgG1, clone 11711,
R&D Systems, Minneapolis, MN, USA). After three washes with ice-cold PBS, cell-
associated immunofluorescence was again determined by FACS analysis. DCs
were similarly analyzed with respect to cell surface expression of CD14, CD40,
CD83 and CD86 using PE-labeled primary antibodies (CD14: clone M5E2, BD
Biosciences; CD40: clone HB14, Miltenyi Biotec; CD83: clone HB15e, R&D
Systems; and CD86: clone 37301, R&D Systems) and a corresponding isotype
control antibody (mouse IgG1, clone 11711, R&D Systems).
Silver staining. The affinity-purified scFv:G28-TRAIL was separated by
SDS-PAGE, and gel was subsequently stained by the help of the PageSilverTM
Silver Staining kit (Fermentas GmbH, St. Leon Rot, Germany). In brief, after
incubation in fixer 1 (50% ethanol, 10% acetic acid) for 60 min and two times in
fixer 2 (30% ethanol) for 20 min, gels were washed twice with deionized water.
Then gels were incubated for 1 min with a sensitizing solution and washed again
twice with deionized water. After 20 min of staining with staining solution and two
washes, protein bands were visualized by adding developing solution. When the
desired signal intensity was achieved, the developer solution was discarded, and
the reaction was terminated by adding stop solution.
Western blotting. For preparation of total cell lysates, cells were harvested in
ice-cold phosphate-buffered saline (PBS) and centrifuged (3 min, 2300 r.p.m.,
4 1C), and the pellet was directly lysed in 4 Laemmli sample buffer (8% SDS,
10% b-mercaptoethanol, 40% glycerol, 0.2 M Tris, pH 8.0) supplemented with
phosphatase inhibitor mixture II (Sigma) and protease inhibitor (Roche
Diagnostics, Mannheim, Germany). Protein samples were boiled for 5 min at
96 1C after 20 s of sonification. Lysates were centrifuged twice (20 min,
14 000 r.p.m.). Samples were separated by SDS-PAGE and transferred to
nitrocellulose membranes. Next, nonspecific binding sites were blocked by
incubation with Tris-buffered saline containing 0.1% Tween-20 and 5% dry milk.
Western blot analyses were performed with primary antibodies specific for
caspase-3 (no. 9662S; Cell Signaling Technology, Danvers, MA, USA), caspase-9
(no. 9502S; Cell Signaling Technology), PARP (clone 7D3-6; BD), caspase-8
(clone C15; Enzo Life Sciences, Lo¨rrach, Germany) and tubulin (clone DM1A; Lab
Vision/NeoMarkers, Fremont, CA, USA). Secondary HRP-conjugated antibodies
Figure 6 CD40 binding enhances caspase activation by scFv:G28 fusion
proteins of TRAILR1- and TRAILR2-specific TRAIL mutants. (a) HeLa and HT1080
cells along with the corresponding CD40 transfectants were incubated for 5 h with
the various scFv:G28-TRAIL variants (10 ng/ml) as indicated. Total cell lysates were
analyzed by western blot for the presence of the indicated proteins. (b) OVCAR3
cells were stimulated with 10 ng/ml of the various scFv:G28-TRAIL variants in the
presence and absence of scFv:G28-Fc (30 min pretreatment). Cells were analyzed
for caspase processing after 5 h
Figure 7 scFv:G28-TRAIL stimulate CD40 signaling. (a) HeLa cells and HeLa-CD40 transfectants were challenged in triplicates with scFv:G28-TRAIL and Killer-TRAIL
and after 8 h supernatants were analyzed by ELISA for the presence of IL-8. (b) HeLa-CD40 transfectants were sensitized for apoptosis induction with CHX (2.5mg/ml) and
otherwise treated as in a. Cell viability was determined next day by crystal violet staining
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Figure 8 scFv:G28-TRAIL fusion proteins stimulate DC maturation. (a) Immature DCs (iDCs) and DCs (mDCs) that have been matured with the gold standard (mixture of
20 ng/ml TNF, 10 ng/ml IL1b, 20 ng/ml IL-6 and 1 mg/ml PGE2) were analyzed by FACS with respect to the cell surface expression of the indicated proteins. (b) iDCs and
mDCs were challenged with scFv:G28-TRAIL variants, Killer-TRAIL or a cytotoxic cocktail (100 ng/ml Fc-CD95L, 5 mg/ml CHX and 0.5% sodium azide). Next day, cellular
viability was determined using the MTT assay and normalized according to cells treated with the cytotoxic cocktail. (c) iDCs were treated for 48 h with 200 ng/ml of the various
scFv:G28-TRAIL variants, with 200 ng/ml scFv:G28-TNC-GpL, a tenascin-C trimerization domain-containing fusion protein of scFv:G28 and the Gaussia princeps luciferase or
with Killer-TRAIL (200 ng/ml). A supernatant of mock transfected HEK293 cells were included as a negative control for scFv:G28-TNC-GpL. To evaluate DC maturation, cells
were analyzed by FACS with respect to the cell surface expression of CD83 and CD86 and compared with untreated groups and DCs were incubated with the ‘gold standard’
mixture. (d) iDCs were treated in triplicates with the indicated concentrations of the various scFv:G28-TRAIL variants as well as with Killer-TRAIL (200 ng/ml), the gold standard
mixture, LPS (100 ng/ml), scFv:G28-TNC-GpL and a control supernatant of mock transfected HEK293 cells. Where indicated, samples were heat-inactivated (HI) at 70 1C for
30 min to check for heat-stable endotoxin contaminations. DC supernatants were assayed after 24 h for the production of IL12 by ELISA. (e) iDCs were treated in triplicates
with 200 ng/ml scFv:G28-TRAIL or LPS (20 ng/ml). Where indicated, samples were HI at 70 1C for 30 min or treated with 50mg/ml polymyxin B (PMB). After 24 h, DC
supernatants were again assayed for IL12 production by ELISA
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were obtained from Dako (Glostrup, Denmark; anti-mouse IgG) and Cell Signaling
(anti-rabbit IgG), and antigen-antibody complexes were visualized using the ECL
Western blotting detection system (Amersham Biosciences, Freiburg, Germany)
according to the protocol delivered by the manufacturer.
IL-8 ELISA analysis. Cells were seeded (2 104 cells/well) in 96-well tissue
cultures plates in 100ml of RPMI 1640 medium with 10% FCS. The next day,
medium was exchanged to minimize the background of constitutive IL-8
production, and cells were stimulated for 8 h in triplicates with the indicated
concentrations of scFv:G28-TRAIL and Killer-TRAIL (Enzo Life Sciences).
Supernatants were analyzed for production of IL-8 using the BD OptEIA Human
IL-8 ELISA Set (BD Biosciences) according to the manufacturer’s instructions.
Isolation, cultivation, and stimulation of monocyte-derived
DCs. PBMCs were isolated from the blood from healthy donors by density
gradient centrifugation with lymphocyte separation medium (PAA Laboratories).
Magnetic bead separation with anti-CD14-coated beads (Miltenyi Biotec) were
used to separate monocytes from the PBMCs. Purified monocytes were
immediately seeded in 10 cm plates with RPMI 1640, 10% FCS and 1% penicillin.
To induce differentiation to immature DCs, 50 ng/ml GM-CSF and 30 ng/ml IL-4
(ImmunoTools, Friesoythe, Germany) were added every second day. After 7 days,
immature DCs were evaluated by FACS analysis for cell surface expression of
CD14, CD40, CD83 and CD86 (see above). Immature DCs were seeded (4 104
cells/well) in 96-well tissue cultures plates in 100ml of RPMI 1640 medium with
10% FCS. Cells were then treated overnight with the various TRAIL fusion
proteins, Killer-TRAIL, scFv:G28-TNC-GpL and gold standard, a mixture
composed of TNF (purified protein, produced using HEK293 cells), IL1b (R&D
Systems), IL-6 (Miltenyi Biotec) and prostaglandin E2 (PGE2, Biomol, Hamburg,
Germany), to evaluate the DC-stimulating activities of these reagents. To test the
various scFv-TRAIL fusion proteins for contaminations with endotoxin, the
corresponding samples were heat-inactivated for 30 min at 70 1C. DCs treated in
parallel with LPS (Sigma-Aldrich) served as a heat-resistant control. As an
additional test for endotoxin contaminations, the effect of the LPS-inhibitory
antibiotic polymyxin B (InvivoGen, San Diego, CA, USA) on IL12 production was
evaluated. On the next day, supernatants were analyzed for production of IL12
using R&D Systems Human IL12 ELISA DuoSet according to the manufacturer’s
instructions. In addition, cell viability was determined using the MTT assay.
Maturation of DCs was further analyzed by FACS analysis of the DC markers
CD83 and CD86 48 h post stimulation. To evaluate TRAIL sensitivity of mature
DCs, the latter were generated by 24 h treatment with TNF (1 mg/ml) and then
challenged with the 200 ng/ml of various TRAIL fusion proteins and Killer-TRAIL.
Finally, cell viability was again analyzed by MTT staining.
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